This Article Full Text Full Text (PDF) All Versions of this Article: 37/4/1075    most recent 01.STR.0000209239.71702.cev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hylek, E. M. Articles by Regan, S. Search for Related Content PubMed PubMed Citation Articles by Hylek, E. M. Articles by Regan, S. Related Collections Coumarins Thrombosis risk factors Anticoagulants

(Stroke. 2006;37:1075.)
© 2006 American Heart Association, Inc.

Original Contributions

Translating the Results of Randomized Trials into Clinical Practice

The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation

Elaine M. Hylek, MD, MPH; James D’Antonio, MD; Carmella Evans-Molina, MD; Carol Shea, RN; Lori E. Henault, MPH Susan Regan, PhD

From the Department of Medicine (E.M.H., L.E.H.), Research Unit-Section of General Internal Medicine, Boston University School of Medicine, Mass; the Department of Medicine (J.D.), Cardiology Division, University of Pittsburgh, Pa; the Department of Medicine (C.E.-M.), University of Virginia, Charlottesville, Va; and the Department of Medicine (C.S., S.R.), Massachusetts General Hospital, Boston, Mass.

Correspondence and Reprint Requests to Elaine M. Hylek, MD, MPH, Boston University School of Medicine, Research Unit-Section of General Internal Medicine, 91 East Concord Street, Suite 200, Boston, MA 02118. E-mail ehylek{at}bu.edu

Background and Purpose— Numerous studies have documented under use of warfarin particularly among elderly patients. A better understanding of the discrepancy between trials and clinical practice will help inform stroke prevention strategies in this vulnerable age group. The study objective was to prospectively assess the use of antithrombotic therapy among a contemporary cohort of patients with atrial fibrillation at the time of hospital discharge. In addition to baseline characteristics, we sought to define the physician-cited reason for not prescribing warfarin for each patient.

Methods— Patients with atrial fibrillation were prospectively identified and followed to hospital discharge. Enrolled patients were 65 years of age, not taking warfarin on admission, and had their longitudinal care provided at our institution. Predictors of warfarin use were determined and physician-cited contraindications were compared across age groups.

Results— Fifty-one percent (n=206) of patients were discharged on warfarin: 75% of those 65 to 69 years of age, 59% 70 to 79, 45% 80 to 89, and 24% age 90 years. Of the remaining 199 patients, 83% had 2 major risk factors for stroke, and 98% were felt to have contraindications including nearly 25% who were unable to tolerate warfarin in the past. Among patients age 80, falling was the most often physician-cited reason for not prescribing warfarin (41%) followed by hemorrhage (28%).

Conclusion— Our findings suggest that many elderly patients at high risk for stroke may not be optimal candidates for anticoagulant therapy. There is a pressing need for alternative stroke prevention strategies for this expanding patient population.

Key Words: atrial fibrillation • geriatrics • warfarin

This article has been cited by other articles:

				D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]

				S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf Response to Letter Regarding Article, "Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation" Circulation, February 5, 2008; 117(5): e150 - e150. [Full Text] [PDF]

				J. S. Taggar and G. Y.H. Lip Anticoagulation for elderly patients with atrial fibrillation: not to be neglected Europace, January 1, 2008; 10(1): 1 - 2. [Full Text] [PDF]

				G. A. Ford, A. M. Choy, P. Deedwania, D. G. Karalis, C.-J. Lindholm, W. Pluta, L. Frison, S. B. Olsson, and on behalf of the SPORTIF III, V Investigators Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trials Stroke, November 1, 2007; 38(11): 2965 - 2971. [Abstract] [Full Text] [PDF]

				S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation Circulation, July 24, 2007; 116(4): 449 - 455. [Full Text] [PDF]

				E. M. Hylek, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation Circulation, May 29, 2007; 115(21): 2689 - 2696. [Abstract] [Full Text] [PDF]

				L. Testa, G. Trotta, A. Abbate, P. Agostoni, and G. G.L. Biondi-Zoccai The Hurdles of Warfarin and the Hurdles of Clinical Practice Stroke, December 1, 2006; 37(12): 2867 - 2867. [Full Text] [PDF]

				A. Ono, I. Kawamura, and T. Fujita Eligibility for Anticoagulation in Elderly Patients With Atrial Fibrillation Stroke, September 1, 2006; 37(9): 2205 - 2205. [Full Text] [PDF]

				C. Stollberger, J. Finsterer, and B. Schneider Safety of Oral Anticoagulation in Elderly Atrial Fibrillation Patients to Prevent Strokes Stroke, August 1, 2006; 37(8): 1960 - 1961. [Full Text] [PDF]

				Elders with AFib Who Are Discharged Without Warfarin Journal Watch Cardiology, May 4, 2006; 2006(504): 3 - 3. [Full Text]